Skip to main content

Advertisement

SpringerLink
Log in

Comment on “Sodium glucose cotransporter 2 inhibitors and gout risk”

  • LETTER TO THE EDITOR
  • Published:
Clinical Rheumatology Aims and scope Submit manuscript

The Original Article was published on 02 June 2023

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Data availability

This is a letter to the editor. No raw data are available.

References

  1. Wood DT, Waterbury NV, Lund BC (2023) Sodium glucose cotransporter 2 inhibitors and gout risk: a sequence symmetry analysis. Clin Rheumatol 42:2469–2475

    Article  PubMed  Google Scholar 

  2. Chung MC, Hung PH, Hsiao PJ, Wu LY, Chang CH, Wu MJ et al (2021) Association of sodium-glucose transport protein 2 inhibitor use for type 2 diabetes and incidence of gout in Taiwan. JAMA Netw Open 4:e2135353

    Article  PubMed  PubMed Central  Google Scholar 

  3. Dominguez Rieg JA, Xue J, Rieg T (2020) Tubular effects of sodium-glucose cotransporter 2 inhibitors: intended and unintended consequences. Curr Opin Nephrol Hypertens 29:523–530

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Novikov A, Fu Y, Huang W, Freeman B, Patel R, van Ginkel C et al (2019) SGLT2 inhibition and renal urate excretion: role of luminal glucose, GLUT9, and URAT1. Am J Physiol Renal Physiol 316:F173–F185

    Article  CAS  PubMed  Google Scholar 

  5. Banerjee M, Pal R, Mukhopadhyay S (2022) Can SGLT2 inhibitors prevent incident gout? A systematic review and meta-analysis. Acta Diabetol 59:783–791

    Article  CAS  PubMed  Google Scholar 

  6. Lai SW, Hwang BF, Kuo YH, Liu CS, Liao KF (2023) Sodium-glucose cotransporter-2 inhibitors use and the risk of gout: a systematic review and meta-analysis. Front Endocrinol (Lausanne) 14:1158153

    Article  PubMed  Google Scholar 

  7. Petri H, Leufkens H, Naus J, Silkens R, van Hessen P, Urquhart J (1990) Rapid method for estimating the risk of acutely controversial side effects of prescription drugs. J Clin Epidemiol 43:433–439

    Article  CAS  PubMed  Google Scholar 

  8. Lund LC, Højlund M, Henriksen DP, Hallas J, Kristensen KB (2021) Sodium-glucose cotransporter-2 inhibitors and the risk of gout: a Danish population based cohort study and symmetry analysis. Pharmacoepidemiol Drug Saf 30:1391–1395

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. College of Medicine, China Medical University, Taichung, Taiwan

    Shih-Wei Lai & Chiu‑Shong Liu

  2. Department of Family Medicine, China Medical University Hospital, Taichung, Taiwan

    Shih-Wei Lai & Chiu‑Shong Liu

  3. Department of Occupational Safety and Health, College of Public Health, China Medical University, Taichung, Taiwan

    Bing-Fang Hwang

  4. College of Medicine, Tzu Chi University, Hualien, Taiwan

    Kuan-Fu Liao

  5. Division of Hepatogastroenterology, Department of Internal Medicine, Taichung Tzu Chi Hospital, No.66, Sec. 1, Fongsing Road, Tanzi District, Taichung City, 427, Taiwan

    Kuan-Fu Liao

Authors
  1. Shih-Wei Lai
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Bing-Fang Hwang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Chiu‑Shong Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Kuan-Fu Liao
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Shih-Wei Lai contributed to the conception of the study, initiated the draft of the study, and approved the final draft.

Bing-Fang Hwang, Chiu-Shong Liu and Kuan-Fu Liao interpreted the data.

Corresponding author

Correspondence to Kuan-Fu Liao.

Ethics declarations

Conflict of interest

The authors disclose no conflicts of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lai, SW., Hwang, BF., Liu, C. et al. Comment on “Sodium glucose cotransporter 2 inhibitors and gout risk”. Clin Rheumatol 43, 835–836 (2024). https://doi.org/10.1007/s10067-023-06791-6

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10067-023-06791-6

Search

Navigation